Sudeep Pharma Ltd (SUDEEPPHRM) Q1FY27 Management Mirror - Jun-2026 Qtr
Consolidated EBITDA Margin Reaffirmed at 37%-38% Long-Term Target; Q1 FY27 Reported at 34.7%
In the Mar'26 Qtr concall, management guided that consolidated EBITDA margins were expected to gradually return to historical levels of 37% to 38% in FY27. In the subsequent Jun'26 Qtr concall, management reaffirmed its long-term target of sustaining consolidated EBITDA margins between 37% and 38%. According to the Quarterly Financial Results for the Jun'26 Qtr (Q1 FY27), the consolidated EBITDA margin was reported as an actual of 34.7%.
5 more themes on the ELITE plan.